Lexaria Bioscience Corp.

NasdaqCM:LEXX Rapport sur les actions

Capitalisation boursière : US$40.5m

Lexaria Bioscience Croissance future

Future contrôle des critères 2/6

Lexaria Bioscience is forecast to grow earnings and revenue by 49.1% and 62.6% per annum respectively while EPS is expected to grow by 48.7% per annum.

Informations clés

49.1%

Taux de croissance des bénéfices

48.7%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices23.7%
Taux de croissance des recettes62.6%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour23 Jul 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:LEXX - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
8/31/20274-17N/AN/A1
8/31/20261-9N/AN/A2
8/31/20251-7N/A-43
8/31/20240-5N/A-33
5/31/20240-5-5-5N/A
2/29/20240-5-5-5N/A
11/30/20230-6-6-6N/A
8/31/20230-7-6-6N/A
5/31/20230-7-6-5N/A
2/28/20230-7-5-5N/A
11/30/20220-7-5-5N/A
8/31/20220-7-5-5N/A
5/31/20220-7-5-5N/A
2/28/20220-7-5-5N/A
11/30/20210-7-5-4N/A
8/31/20211-6-4-4N/A
5/31/20211-5-4-3N/A
2/28/20211-4-3-3N/A
11/30/20201-4-3-3N/A
8/31/20200-4-3-3N/A
5/31/20200-4-3-3N/A
2/29/20200-4-3-3N/A
11/30/20190-4-4-3N/A
8/31/20190-4-4-3N/A
5/31/20190-4-4-3N/A
2/28/20190-6-3-3N/A
11/30/20180-7-3-3N/A
8/31/20180-7-3-3N/A
5/31/20180-6-2-2N/A
2/28/20180-3N/A-2N/A
11/30/20170-2N/A-2N/A
8/31/20170-2N/A-2N/A
5/31/20170-1N/A-1N/A
2/28/20170-1N/A-1N/A
11/30/20160-1N/A-1N/A
8/31/20160-1N/A-1N/A
5/31/20160-1N/A-1N/A
2/29/20160-2N/A-1N/A
11/30/20150-2N/A-2N/A
8/31/20150-2N/A-2N/A
5/31/20150-2N/A-1N/A
2/28/20150-2N/A-1N/A
11/30/2014N/A-2N/A-1N/A
8/31/2014N/A-2N/A-1N/A
7/31/20141-1N/A0N/A
4/30/20141-1N/A0N/A
1/31/201410N/A0N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: LEXX is forecast to remain unprofitable over the next 3 years.

Bénéfices vs marché: LEXX is forecast to remain unprofitable over the next 3 years.

Croissance élevée des bénéfices: LEXX is forecast to remain unprofitable over the next 3 years.

Chiffre d'affaires vs marché: LEXX's revenue (62.6% per year) is forecast to grow faster than the US market (8.9% per year).

Croissance élevée des revenus: LEXX's revenue (62.6% per year) is forecast to grow faster than 20% per year.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if LEXX's Return on Equity is forecast to be high in 3 years time


Découvrir les entreprises en croissance